383 related articles for article (PubMed ID: 16569535)
1. The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy.
Goodman SG; Bozovich GE; Tan M; Dos Santos A; Gurfinkel EP; Cohen M; Langer A;
Am Heart J; 2006 Apr; 151(4):791-7. PubMed ID: 16569535
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
[TBL] [Abstract][Full Text] [Related]
3. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
Santopinto J; Gurfinkel EP; Torres V; Marcos E; Bozovich GE; Mautner B; McCabe CH; Antman EM
Am Heart J; 2001 Apr; 141(4):566-72. PubMed ID: 11275921
[TBL] [Abstract][Full Text] [Related]
4. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy.
Cohen M; Stinnett SS; Weatherley BD; Gurfinkel EP; Fromell GJ; Goodman SG; Fox KA; Califf RM
Am Heart J; 2000 Jun; 139(6):962-70. PubMed ID: 10827375
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
[TBL] [Abstract][Full Text] [Related]
6. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
[TBL] [Abstract][Full Text] [Related]
7. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
Cohen M; Mahaffey KW; Pieper K; Pollack CV; Antman EM; Hoekstra J; Goodman SG; Langer A; Col JJ; White HD; Califf RM; Ferguson JJ;
J Am Coll Cardiol; 2006 Oct; 48(7):1346-54. PubMed ID: 17010793
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
[TBL] [Abstract][Full Text] [Related]
9. ST-segment deviation on the admission electrocardiogram, treatment strategy, and outcome in non-ST-elevation acute coronary syndromes A substudy of the Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) Trial.
Windhausen F; Hirsch A; Tijssen JG; Cornel JH; Verheugt FW; Klees MI; de Winter RJ;
J Electrocardiol; 2007; 40(5):408-15. PubMed ID: 17604045
[TBL] [Abstract][Full Text] [Related]
10. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
[TBL] [Abstract][Full Text] [Related]
12. ESSENCE trial results: breaking new ground. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events.
Demers C
Can J Cardiol; 1998 Aug; 14 Suppl E():15E-19E. PubMed ID: 9779028
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: Insights from the TRANSFER-AMI trial.
Lavi S; Cantor WJ; Casanova A; Tan MK; Yan AT; Džavík V; Fitchett D; Cohen EA; Borgundvaag B; Heffernan M; Ducas J; Goodman SG
Am Heart J; 2012 Feb; 163(2):176-81.e2. PubMed ID: 22305834
[TBL] [Abstract][Full Text] [Related]
14. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis.
Giraldez RR; Nicolau JC; Corbalan R; Gurfinkel EP; Juarez U; Lopez-Sendon J; Parkhomenko A; Molhoek P; Mohanavelu S; Morrow DA; Antman EM
Eur Heart J; 2007 Jul; 28(13):1566-73. PubMed ID: 17562672
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice.
Zeymer U; Gitt A; Jünger C; Koeth O; Zahn R; Wienbergen H; Gottwik M; Senges J;
Am J Cardiol; 2006 Jul; 98(1):19-22. PubMed ID: 16784913
[TBL] [Abstract][Full Text] [Related]
16. A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study.
Scirica BM; Morrow DA; Sadowski Z; Ruda M; Nicolau JC; Giugliano RP; Wiviott SD; Sabatine MS; Shui A; Antman EM; Braunwald E
Eur Heart J; 2007 Sep; 28(17):2070-6. PubMed ID: 17600039
[TBL] [Abstract][Full Text] [Related]
17. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
Morrow DA; Antman EM; Murphy SA; Qin J; Ruda M; Guneri S; Jacob AJ; Budaj A; Braunwald E;
Am Heart J; 2007 Dec; 154(6):1078-84, 1084.e1. PubMed ID: 18035078
[TBL] [Abstract][Full Text] [Related]
18. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Mahaffey KW; Ferguson JJ
Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952
[TBL] [Abstract][Full Text] [Related]
19. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.
Murphy SA; Gibson CM; Morrow DA; Van de Werf F; Menown IB; Goodman SG; Mahaffey KW; Cohen M; McCabe CH; Antman EM; Braunwald E
Eur Heart J; 2007 Sep; 28(17):2077-86. PubMed ID: 17600038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
